| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8615506 | Clinical Lymphoma Myeloma and Leukemia | 2018 | 32 Pages |
Abstract
Ponatinib plus chemotherapy might be associated with better outcomes than chemotherapy with earlier generation TKIs in patients with newly diagnosed Ph+ ALL.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Elias Jabbour, Maral DerSarkissian, Mei Sheng Duh, Nora McCormick, Wendy Y. Cheng, Lisa J. McGarry, Ariadne Souroutzidis, Hui Huang, Susan O'Brien, Farhad Ravandi, Hagop M. Kantarjian,